SEGMENT REPORTING (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Components Optimization Charges

The following table presents the OPTAVIA segment's revenue, significant segment expenses, and segment net income for the three months ended September 30, 2025 and 2024, respectively:

	September 30, 2025		September 30, 2024
Revenue	$	89,409	$	140,163
Less:
Cost of sales	27,250		34,489
Selling, marketing, and after sales support	41,543		74,867
Distribution	3,815		6,138
Technology	11,123		12,481
Administrative and corporate support functions	8,849		9,476
Equity compensation	910		606
Other loss (income) (1)	(1,424)		528
Provision (benefit) for income taxes	(396)		449
Segment net income (loss)	$	(2,261)	$	1,129
Reconciliation of profit or loss
Adjustments and reconciling items	—		—
Consolidated net income (loss)	$	(2,261)	$	1,129

(1) Other loss (income) included within Segment net income (loss) includes interest income, interest expense, and unrealized gains and losses on LifeMD common stock.

The following table presents the OPTAVIA segment's revenue, significant segment expenses, and segment net income for the nine months ended September 30, 2025 and 2024, respectively:

	September 30, 2025		September 30, 2024
Revenue	$	310,692	$	483,460
Less:
Cost of sales	87,645		127,056
Selling, marketing, and after sales support	151,883		242,560
Distribution	13,646		32,196
Technology	32,731		38,651
Administrative and corporate support functions	25,730		35,597
Equity compensation	5,467		5,231
Other income (1)	(7,153)		(343)
Provision for income taxes	1,296		1,222
Segment net income	$	(553)	$	1,290
Reconciliation of profit or loss
Adjustments and reconciling items	—		—
Consolidated net income (loss)	$	(553)	$	1,290

(1) Other income included within Segment net income includes interest income, interest expense, and realized and unrealized gains and losses on LifeMD common stock.